Company: RGNX
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0000950170-25-038770
Chunk: 69

Company: REGENXBIO Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 16
Chunk 69
---
.

126

18. Supplemental DisclosuresOther Current AssetsOther current assets consisted of the following (in thousands): 

        As of December 31,

        2024

        2023

        Net cost reimbursement due from collaborators
         
        $
        11,304

        $
        17,745

        Accrued interest on investments

        1,094

        1,551

        Other

        1,376

        1,107

        $
        13,774

        $
        20,403

       Accrued Expenses and Other Current LiabilitiesAccrued expenses and other current liabilities consisted of the following (in thousands): 

        As of December 31,

        2024

        2023

        Accrued personnel costs
         
        $
        17,607

        $
        18,146

        Accrued external research and development expenses

        8,998

        13,762

        Accrued sublicense fees and royalties

        8,658

        14,234

        Accrued external general and administrative expenses

        2,002

        2,717

        Accrued purchases of property and equipment

        156

        386

        Other accrued expenses and current liabilities

        649

        458

        $
        38,070

        $
        49,703

       Supplemental Disclosures of Non-cash Investing and Financing ActivitiesPurchases of property and equipment included in accounts payable and accrued expenses and other current liabilities as of December 31, 2024 were $0.3 million, a net decrease of $0.1 million from December 31, 2023. Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities as of December 31, 2023 were $0.4 million, a net decrease of $2.1 million from December 31, 2022. Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities as of December 31, 2022 were $2.5 million, a net decrease of $7.5 million from December 31, 2021. Offering expenses for at-the-market offering programs included in accounts payable and accrued expenses and other liabilities as of December 31, 2024 and 2023 were $0.2 million and less than